NYSAM Virtual Annual Meeting February 5-6, 2021

2021 NYSAM Annual Virtual Meeting

Please note: The registration is a 2-step process:
1) You pay for the conference through PayPal, and then
2) You will receive two links to your email within 24 hours. You must register for the Zoom meetings with these links for each of the two days. The links you receive will be unique to the registrant and are not transferrable.

To Begin the Payment/Registration Process, Please Click Here

This year’s meeting has been approved for 9 AMA PRA Category 1 Credit(s)™. Please see the agenda below for both days below. 

Dear NYSAM Members,

The dates for our next annual meeting to be held virtually are:

Schedule

Friday, February 5th, 1 pm – 5 pm
The Annual Public Policy Day 
Scheduled topics include: Policy Priorities for 2021 and Beyond; What Will Drug Decriminalization Legislation Mean for Addiction Prevention and Treatment in Oregon?; Nursing Facilities and MOUD Access; Update on New ASAM Policy Statements

Saturday, February 6th, 8 am – 1:30 pm
The Annual Scientific and Treatment Conference
Scheduled topics include: Clinical Case Presentations; Treatment of SUD in the Context of COVID-19; XR Buprenorphine in Clinical Practice; Stimulant Use Disorder and Potential Therapeutics; and Toxicology Panel: Cases in Toxicology

1. Learners will list at least 3 initiatives in United States to combat the overdose crisis
2. Learners will describe at least 1 policy priority for New York state addiction medicine practitioners
3. Learners will describe regulations regarding telemedicine and potential changes post-COVID-19

Speakers:
Yngvild Olsen, MD MPH, Vice-President, American Society of Addiction Medicine
Mitchell Nuland, MA, Advocacy and Gov’t Relations, American Society of Addiction Medicine
Kelly Ramsey, MD MPH, Associate Chief of Addiction Medicine, OASAS

Break: 1:50 pm-2 pm

Session 2: “What will drug decriminalization mean for addiction prevention and treatment – Oregon’s Measure 110” 2 pm-3:20 pm

Objectives:

1. Learners will list key components of Oregon’s Drug Decriminalization and Addiction Treatment Initiative
2. Learners will describe at least one international example of drug decriminalization
3. Learners will describe similarities and differences between Oregon and New York State regarding addiction treatment services

Speakers:
Morgan Godvin, Commissioner, Oregon Alcohol and Drug Policy Commission
Beau Kilmer, PhD, Director, RAND Drug Policy Research Center
Moxie Loeffler, DO MPH, President Oregon Society of Addiction Medicine
Eric Richardson, Executive Director, Eugene/Springfield NAACP

Break: 3:20 pm-3:30 pm

Session 3:  “Do nursing facilities discriminate against patients receiving medications for opioid use disorder (MOUD)?” 3:30 pm-4:30 pm

Objectives:

1. Learners will describe legal protections for patients with opioid use disorder who take MOUD
2. Learners will list several actions they can take to work with nursing facilities to improve care for patients with opioid use disorder who take MOUD

Speakers:
Rebekah Joab, JD, Staff Attorney, Legal Action Center
Simeon Kimmel, MD MA, Assistant Professor, Boston University School of Medicine
Jade Malcho, MD, Instructor of Clinic Emergency Medicine, U of Rochester Medical Center

Break: 4:30 pm-4:40 pm

Session 4: “An update on new ASAM policy statements” 4:40 pm-5 pm

Objectives:

1. Learners will describe the rationale for providing medications for opioid use disorder in criminal justice settings
2. Learners will describe the implications of cannabis legalization for addiction medicine practitioners

Speakers:
Jeffrey Selzer, MD, Secretary, American Society of Addiction Medicine
Norm Wetterau, MD, Clinical Associate Professor of Family Medicine, U of Rochester Medical Center
Aaron Fox, MD MS, Associate Professor of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine

1. Learners will describe the outcome of an interesting case
2. Learners will describe the outcome of an interesting case
3. Learners will describe regulations regarding telemedicine and potential changes post-COVID-19

Speakers:
Edwin A. Salsitz, MD, DFASAM, Associate Clinical Professor of Psychiatry at the Mount Sinai School of Medicine
Timothy J. Wiegand, MD, Director of Medical Toxicology and Toxicology Consult Service, URMC and Strong Memorial Hospital

Welcome and NYSAM Lifetime Achievement Award 8:50 am-9:10 am

Break: 9:10 am-9:20 am

Session 2: “Treating SUD in the Context of COVID-19” 9:20 am-10:10 am

Objectives:

1. Learners will describe the epidemiology of overdoses pre-COVID-19 and during COVID-19
2. Learners will describe changes in SUD during COVID-19
3. Learners will describe the risks of COVID-19 with PWUD
4. Learners will describe the changes in regulations regarding SUD delivery of treatment services during COVID-19
5. Learners will describe innovative practices in the delivery of SUD treatment services during COVID-19

Speaker:
Kelly S. Ramsey, MD, MPH, MA, FACP, Associate Chief of Addiction Medicine, NYS OASAS

Break: 10:10 am-10:20 am

Session 3: “XR Buprenorphine: To inject or not to inject, that is the question” 10:20 am-11:10 am

Objectives:

1. Learners will describe an overview of XR buprenorphine
2. Learners will describe patient selection for XR buprenorphine
3. Learners will describe clinical operations for XR buprenorphine shipping, storage, and administration

Speaker:

Nicholas Batson, MD, MMM, Division Lead for Psychiatry, Crystal Run Healthcare

Break: 11:10 am-11:20 am

Session 4: “Stimulant Use Disorder: A Persistent Problem in Need of New Therapeutic Options” 11:20 am-12:10 pm

Objectives:

1. Learners will describe the pharmacologic strategies’ approaches utilized to test treatments of stimulant use disorders
2. Learners will describe what pharmacologic strategies show promise for the treatment of cocaine use disorders
3. Learners will describe the methodologic and practical limitations of current research impeding discovery of an FDA-approved medication for cocaine use disorders

Speaker:
Frances Rudnick Levin, MD, Kennedy-Leavy Professor of Psychiatry at Columbia University and the Chief of the Division on Substance Use Disorders at NYSPI/Columbia University

Break: 12:10 pm-12:20 pm

Session 5: “The Toxicology Panel -Case Based Discussion of Hot Topics in Addiction/Toxicology!” 12:20 pm-1:20 pm
Objectives:

1. Learners will describe the prevalence, pharmacology, and toxicology of designer benzodiazepines in the United States illicit drug market
2. Learners will describe the precipitated withdrawal syndrome and how to mitigate risk and treat the syndrome when it occurs during buprenorphine initiation
3. Learners will describe three specific designer benzodiazepines that have been encountered in the United States
4. Learners will describe the drugs described as “gabapentinoids”
5. Learners will describe how fentanyl pharmacology is altered with high dose drug use over prolonged periods of time
6. Learners will describe how gabapentin intoxication appears clinically

Moderator: Timothy J. Wiegand, MD, Director of Medical Toxicology and Toxicology Consult Service, URMC and Strong Memorial Hospital

Speakers:
Lewis S. Nelson, MD, Chair, Department of Emergency Medicine, Rutgers New Jersey Medical School
Jeanmarie Perrone, MD, Director of the Division of Medical Toxicology and the founding Director of the Penn Center for Addiction Medicine and Policy
JoAn Laes, MD, an addiction medicine physician at Hennepin Healthcare in Minneapolis, MN
Ross Sullivan, MD, Director, SUNY Upstate Emergency Opioid Bridge Clinic and Fellowship Director of Medical Toxicology
Paul Wax, MD, Executive Director of the American College of Medical Toxicology.
Closing: 1:20 pm-1:30 pm